The Hippo pathway in cell growth, organ size, and Tumorigenesis
The Hippo pathway is crucial in organ size control and its dysregulation contributes to tumorigenesis. Core components of the Hippo pathway include the protein kinases of MST1/2, MAP4Ks, LATS1/2, the transcription co-activators YAP/TAZ and their DNA binding partners TEADs. LATS phosphorylates YAP/TAZ to promote cytoplasmic localization and degradation, thereby inhibiting YAP/TAZ and cell growth. The Hippo pathway is regulated by a wide range of signals, including cell density, GPCR, cellular energy levels, and mechanical cues. We recently discovered that TEAD shuttles to cytoplasm in a Hippo independent manner. Moreover, the Hippo pathway also plays a critical role in suppressing cancer immunity. The emerging role of the Hippo pathway in tumorigenesis suggests potential therapeutic value of targeting this pathway for cancer treatment.
Date: 20 June 2018, 11:00 (Wednesday, 9th week, Trinity 2018)
Venue: NDM Building, Headington OX3 7FZ
Venue Details: Basement seminar room, TDI
Speaker: Professor Kun-Liang Guan (UCSD)
Organising department: Ludwig Institute for Cancer Research, Oxford Branch
Organiser: Christina Woodward (Oxford Ludwig Institute, Nuffield Department of Medicine, University of Oxford)
Organiser contact email address: christina.woodward@ludwig.ox.ac.uk
Host: Prof Xin Lu (Ludwig Cancer Research, Oxford Branch)
Part of: Ludwig Institute Seminar Series
Booking required?: Not required
Audience: Members of the University only
Editor: Christina Woodward